Jim Hoffman: Thrombomodulin as a Key Regulator of Coagulation and Inflammation
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about an article by Yasuyo Shimomura et al. published in Journal of Intensive Care, adding:
“Thrombomodulin (TM) is a protein that plays a crucial role in regulating coagulation and inflammation.
It is primarily expressed on the cell surface of endothelial cells, but its soluble form exists in the circulation as well.
TM, when optimally dosed, has been demonstrated to exert a protective effect against greater endothelial dysfunction and vascular damage during experimental sepsis and coagulopathy.
Recombinant human-soluble TM (rTM) administration has been used in humans, primarily in Japan, for the treatment of sepsis and hematological malignancy-associated disseminated intravascular coagulation DIC, reducing the severity of vascular injury since 2008.
In the context of dysregulated NETosis, which is also prevalent DIC progression, resulting in greater vascular injury, TM is known to inhibit platelet and LPS-facilitated NETosis induction in vitro.
Based on the work of Toh et al., and the enlightening research of many other NETosis investigators; NETosis dysregulation should be directly targeted by extracorporeal depletion therapy to reduce DIC severity and reduce the risk of life-threatening immunothrombotic ischemic events.
NETosis induction and impaired chromatin/NET clearance from the blood positively correlate with an increased risk of life-threatening disseminated intravascular coagulation and ischemic circulatory failure events.”
Title: Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro
Authors: Yasuyo Shimomura, Mika Suga, Naohide Kuriyama, Tomoyuki Nakamura, Toshikazu Sakai, Yu Kato, Yoshitaka Hara, Chizuru Yamashita, Hiroshi Nagasaki, Masao Kaneki, Osamu Nishida
Stay updated on all scientific advances Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy